Page last updated: 2024-12-07

galactose-1-phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

alpha-D-galactose 1-phosphate : A D-galactopyranose 1-phosphate having alpha-configuration at the anomeric centre. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID123912
CHEBI ID17973
SCHEMBL ID285294
MeSH IDM0095183

Synonyms (54)

Synonym
alpha-d-galactopyranosyl phosphate
alpha-d-galactopyranose, 1-(dihydrogen phosphate)
CHEBI:17973 ,
alpha-d-galactopyranose 1-(dihydrogen phosphate)
galactose-1-phosphate
1-o-phosphono-alpha-d-galactopyranose
alpha-d-galactosyl phosphate
alpha-d-galactopyranose, 1-phosphate (6ci)
alpha-d-galactopyranose, 1-(dihydrogen phosphate) (9ci)
galactitol, 1-(dihydrogen phosphate)
galactopyranose, 1-(dihydrogen phosphate), alpha-d- (7ci,8ci)
galactopyranose, 1-phosphate
alpha-d-galactopyranose 1-phosphate
alpha-d-galactose 1-phosphate
C00446
GALACTOSE-1P ,
2255-14-3
d-galactose 1-phosphate
alpha-d-gal-1-p
GL1 ,
alpha-d-galactose-1-phosphate
1Z4N
DB02317
1Z4O
BMSE000151
[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate
4z9z6n3gh4 ,
unii-4z9z6n3gh4
EPITOPE ID:145001
SCHEMBL285294
galactose 1-phosphate
.alpha.-d-galactose 1-phosphate
.alpha.-d-galactose 1-phosphate dipotassium salt pentahydrate
DTXSID80177082
{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phosphonic acid
AKOS027323695
alpha-d-1-(dihydrogen phosphate) galactopyranose
galactopyranose 1-phosphate
1-phosphate a-d-galactopyranose
a-d-galactose 1-phosphate
a-d-galactopyranosyl phosphate
a-d-galactosyl phosphate
a-d-1-(dihydrogen phosphate) galactopyranose
1-(dihydrogen phosphate) galactitol
Q3082858
CS-0062267
HY-113143
(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl dihydrogen phosphate
(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yldihydrogenphosphate
galactopyranose, 1-(dihydrogen phosphate), .alpha.-d-
.alpha.-d-galactopyranose, 1-phosphate
.alpha.-d-galactopyranosyl phosphate
.alpha.-d-galactopyranose, 1-(dihydrogen phosphate)
.alpha.-d-galactosyl phosphate

Research Excerpts

Toxicity

Induced galactose toxicity is prevented by deletion of GAL4. Galactose-1-phosphate, a phosphorylated intermediate of the Leloir pathway, is the toxic compound.

ExcerptReferenceRelevance
" The hypothesized toxic intermediate galactose-1-phosphate cannot be the sole cause of galactose related toxicity, but indications were found that galactose-1-phosphate might cause a negative effect through inhibition of phosphoglucomutase."( The roles of galactitol, galactose-1-phosphate, and phosphoglucomutase in galactose-induced toxicity in Saccharomyces cerevisiae.
Bro, C; de Jongh, WA; Nielsen, J; Olsson, L; Ostergaard, S; Regenberg, B, 2008
)
0.92
" Induced galactose toxicity is prevented by deletion of GAL4, which inhibits the transcriptional activation of genes involved in galactose metabolism and by deletion of the galactokinase (GAL1), indicating that galactose-1-phosphate, a phosphorylated intermediate of the Leloir pathway, is the toxic compound."( Overexpression of the aldose reductase GRE3 suppresses lithium-induced galactose toxicity in Saccharomyces cerevisiae.
Assis, LJ; Masuda, CA; Mendonça-Previato, L; Miranda, MN; Montero-Lomelí, M; Penha, LL; Previato, JO, 2008
)
0.53
" Yet, if this metabolic pathway is perturbed due to congenital deficiencies of the three associated enzymes, or an overwhelming presence of galactose, this monosaccharide which is abundantly present in milk and many non-dairy foodstuffs, will become highly toxic to humans and animals."( Galactose toxicity in animals.
Elsas, LJ; Lai, K; Wierenga, KJ, 2009
)
0.35
"Metabolic dysregulation leading to sugar-phosphate accumulation is toxic in organisms ranging from bacteria to humans."( Common and divergent features of galactose-1-phosphate and fructose-1-phosphate toxicity in yeast.
Bacha-Hummel, JM; Bennett, BD; Botstein, D; Botstein, M; Chen, JC; Gibney, PA; Rabinowitz, JD; Schieler, A; Silverman, SJ; Volpe, M; Xu, Y, 2018
)
0.76
" Utilization of galactose requires a close interplay of the metabolic enzymes, as misregulation or malfunction of individual components can lead to the accumulation of toxic intermediate compounds."( Galactose metabolism and toxicity in Ustilago maydis.
Ammon, A; Dillner, B; Grün, N; Höll, C; Kämper, J; Klebl, F; Schuler, D; Ulrich, J; Voll, LM, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
D-galactopyranose 1-phosphateA D-galactose phosphate that consists of D-galactopyranose having a single phospho substituent located at the 1-position. It is an intermediate obtained during the the galactose metabolism.
alpha-D-hexose 1-phosphateAny hexose-1-phosphate which has D configuration at position 5 and alpha-configuration at the anomeric centre.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (32)

PathwayProteinsCompounds
Metabolism14961108
Carbohydrate metabolism173120
Galactose catabolism410
Galactose Metabolism1234
Nucleotide Sugars Metabolism817
Lactose Synthesis1015
Galactosemia1234
Galactosemia II (GALK)817
Galactosemia III817
Congenital Disorder of Glycosylation CDG-IId1015
GLUT-1 Deficiency Syndrome1015
Galactitol and Galactonate Degradation1416
Galactose Degradation/Leloir Pathway1318
Amino Sugar and Nucleotide Sugar Metabolism II2231
Amino Sugar and Nucleotide Sugar Metabolism III2340
Leloir Pathway612
Amino Sugar and Nucleotide Sugar Metabolism2229
D-Galactose Degradation (Leloir pathway)49
Disease1278231
Diseases of metabolism69121
Diseases of glycosylation2243
Diseases associated with glycosylation precursor biosynthesis621
Defective GALT can cause GALCT02
Galactose metabolism ( Galactose metabolism )913
UDP-D-glucose + D-Galactose 1-phosphate = D-Glucose 1-phosphate + UDP-D-galactose ( Galactose metabolism )14
The impact of Nsp14 on metabolism (COVID-19 Disease Map)084
Disorders of galactose metabolism07
UDP-galactose biosynthesis013
galactose degradation III017
galactose degradation I011
Biochemical pathways: part I0466
Galactose degradation II015

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-phosphoglucomutaseLactococcus lactisKi30.000030.000030.000030.0000AID977610
Chain A, Beta-phosphoglucomutaseLactococcus lactisKi30.000030.000030.000030.0000AID977610
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1811Experimentally measured binding affinity data derived from PDB2005Journal of the American Chemical Society, Apr-20, Volume: 127, Issue:15
Chemical confirmation of a pentavalent phosphorane in complex with beta-phosphoglucomutase.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2005Journal of the American Chemical Society, Apr-20, Volume: 127, Issue:15
Chemical confirmation of a pentavalent phosphorane in complex with beta-phosphoglucomutase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (162)

TimeframeStudies, This Drug (%)All Drugs %
pre-199043 (26.54)18.7374
1990's26 (16.05)18.2507
2000's48 (29.63)29.6817
2010's34 (20.99)24.3611
2020's11 (6.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 57.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index57.09 (24.57)
Research Supply Index5.15 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index92.86 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (57.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.18%)5.53%
Reviews6 (3.53%)6.00%
Case Studies12 (7.06%)4.05%
Observational0 (0.00%)0.25%
Other150 (88.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]